After treatment with gonadotropin, clomiphene, or letrozole, clinical pregnancies occurred in 35.5%, 28.3%, and 22.4% of cycles, and live birth in 32.2%, 23.3%, and 18.7%, respectively; pregnancy ...

Letrozole may help women with polycystic ovary syndrome become pregnant. ScienceDaily . Retrieved June 2, 2025 from www.sciencedaily.com / releases / 2014 / 07 / 140709182159.htm ...

The drug letrozole results in higher birth rates in women with polycystic ovary syndrome (PCOS) than the current preferred infertility treatment drug, according to a nationwide study led by Penn ...

Compared with traditional therapies for ovarian stimulation, letrozole resulted in significantly lower rates of live birth and clinical pregnancy, according to findings published in The New ...

Letrozole, a generic drug, is relatively inexpensive, matching the costs of the long-established clomiphene of about $56 for 30 pills. "This is an affordable form of infertility treatment," Legro ...

Ovulation, conception, pregnancy, and live birth were significantly more likely after treatment with letrozole. The rate of pregnancy loss, the mean pregnancy duration and birth weight, and rates ...

Letrozole (Femara), when used for fertility, can stimulate ovulation in people with PCOS. Learn more about its use and the side effects. Medically reviewed by Renita White, MD Medically reviewed ...

A 750-women government-funded study, one of the largest to date looking at infertility and PCOS, found that the drug letrozole improves ovulation and results in higher pregnancy and live ...

Letrozole(Femara) generic is an aromatase inhibitor, ... • It is only for women who have experienced menopause and cannot become pregnant. Inform your doctor about your pregnancy and lactation.

Letrozole, Gonadotropin, or Clomiphene for Unexplained Infertility. New England Journal of Medicine , 2015; 373 (13): 1230 DOI: 10.1056/NEJMoa1414827 Cite This Page : ...

The clomiphene group had the fewest multiple babies born per pregnancy, at 5.7 percent, compared to 14.3 percent in the letrozole group and 13.4 percent in the group receiving gonadotropins.